Results for: Obesity

A proposed change to the body mass index (BMI) has raised concerns among campaigners, experts, and eating disorder survivors. The researchers suggest lowering the BMI range for people over 40 to 27, arguing that the current threshold for obesity ‘may not be appropriate’ for older adults. However, critics argue that BMI is already an inaccurate measurement and that the proposed change could lead to more people being labeled ‘obese,’ leading to shame and guilt. They also question the accuracy of BMI and its use in determining health outcomes.

A proposed revision to the body mass index (BMI) system could lead to millions of Britons being classified as obese. Under the proposed changes, adults over 40 with a BMI of 27 or higher would be considered obese, significantly expanding the current definition. The authors argue that the current BMI threshold for obesity may not be appropriate for middle-aged and older adults, as bodies tend to experience increased fat accumulation around the waist after age 40. Critics point out that the study did not account for factors such as diet, exercise levels, and sleep patterns, which can influence obesity risk. The BMI system, developed in the 1830s, has faced criticism for its outdated calculation method, which does not distinguish between fat and muscle mass.

A Delhi restaurant’s bizarre marketing strategy that claims eating their ‘chole bhature’ can aid weight loss has gone viral online, eliciting a flurry of amused comments.

Diabetes and obesity are interconnected health conditions with rising prevalence, presenting new challenges. This article explores the latest complications of these conditions, including increased Covid-19 risks, non-alcoholic fatty liver disease, diabetic retinopathy, cardiovascular issues, and nerve damage. To avoid these complications, proactive steps are crucial. These include adopting a healthy lifestyle with balanced nutrition, regular exercise, stress management, and adequate sleep. Regular monitoring and management of blood sugar levels, weight, and other health markers are essential. Staying informed, advocating for personal health, seeking support and community engagement, and working with healthcare professionals for personalized guidance are also vital. By implementing these strategies, individuals can take control of their health and reduce the risk of developing severe complications associated with diabetes and obesity.

Diabetes UK has expressed concern over the sharp rise in type 2 diabetes diagnoses, especially among individuals under the age of 40. The organization highlights the influence of an unhealthy food environment, marked by accessible and affordable unhealthy options. Experts emphasize the need for stringent measures to combat the obesity crisis that underlies the surge in diabetes cases. The charity urges political parties to prioritize healthy food access, affordable housing, and green spaces for young people. It also recommends stricter regulation of junk food advertising and investment in programs supporting those at risk of diabetes complications.

Obesity has become a global crisis, with over 1 billion individuals affected in 2022. In response, the pharmaceutical industry has developed new weight-loss drugs, including Ozempic, which are gaining popularity. Johann Hari’s book, “Magic Pill,” explores the complexities surrounding these medications, addressing both their potential benefits and disturbing risks.

Hari’s narrative revolves around his own experience with Ozempic, as well as interviews with experts, scientists, and individuals affected by obesity. He delves into the science behind the drugs, examining their impact on the body and mind. Additionally, he explores the societal factors that contribute to weight gain, such as the prevalence of processed foods and the erosion of traditional dietary wisdom.

Through a blend of personal stories, scientific evidence, and social commentary, “Magic Pill” provides a comprehensive understanding of the complex relationship between obesity, medication, and overall health. It raises important questions about the ethical implications of using weight-loss drugs, the long-term effects on individuals and society, and the need for systemic changes to address the root causes of obesity.

Eli Lilly’s popular obesity and diabetes drugs, Mounjaro and Zepbound, are facing ongoing shortages that are limiting their supply and impacting the company’s earnings. According to analysts, these shortages could result in lower revenue and earnings per share for the first quarter. The company is working to ramp up manufacturing to meet the demand, but the impact on earnings remains a concern. Investors will be watching for updates on manufacturing capacity, pricing, and coverage decisions from insurers as they assess the impact on Lilly’s financial performance.

While alternative weight loss remedies may seem appealing, it’s crucial to be aware of their potential side effects and risks. Some of these remedies, such as appetite suppressants, steroids, herbal tonics, and protein powders, may lead to liver, kidney, or intestinal issues. It’s essential to consult a medical professional before using any alt remedies, as they may interact differently with different bodies and can have elevated side effects in individuals with compromised immunity or other health conditions. Genuine and authentic medicines can also cause harm if not taken under proper supervision. It’s always advisable to rely on balanced meals, appropriate exercises, and avoid fad diets and processed foods for healthy and sustainable weight loss.

Hattie Cronk, a mother of two, struggled with weight issues throughout her life, leading to a 65-pound weight gain after her second child. Determined to break free from unhealthy habits and reduce her risk of chronic disease, she sought professional support and embarked on a journey of self-improvement. Through medication, a healthy relationship with food, strength training, and unwavering determination, Cronk has lost 65 pounds, reduced her BMI to a healthy range, and now enjoys a renewed sense of energy, strength, and confidence.

Around 3.6 million older Americans are now eligible for Medicare coverage of Novo Nordisk’s weight-loss drug Wegovy, following FDA approval for expanded use in reducing cardiovascular risks. The new approval allows for Medicare Part D plans to cover Wegovy for individuals who are overweight or obese and have both heart disease and obesity.